secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039783
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q2 2023: cash $385M, FT522 Phase 1 start-up, FT825 IND planned 2H23
--------------------------------------------------------------------------------

- Cash position $385.2M as of June 30, 2023; runway into 2H25.
- Q2 2023 revenue $0.9M from ONO collaboration; GAAP op ex $63.5M incl $12.9M stock comp.
- Phase 1 start-up for FT522 ADR-armed CAR NK program; IND allowed May 2023.
- IND submission planned 2H23 for FT825/ONO-8250 HER2-targeted CAR T program under ONO collaboration.
- FT576 BCMA-targeted CAR NK and FT819 CD19-targeted CAR T programs enrolling patients in dose escalation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017023039783/0000950170-23-039783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017023039783/fate-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer